GeoVax Labs initiated with a Buy at Alliance Global Partners

Alliance Global Partners analyst James Molloy initiated coverage of GeoVax Labs (GOVX) with a Buy rating and $15 price target Lead candidate GEO-CM04S1 is a “potentially best-in-class” COVID-19 prophylactic with potential in both healthy and immunocompromised patients, notes the analyst, who attributes $12.25 per share in value to CMO4S1. The firm also attributes $2 per share in value to Gedeptin, a head and neck cancer injectable therapeutic that the company is also advancing, along with cash and the remaining technology being valued at 75c per share.